Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SYRE

+ Watchlist+ Portfolio

Spyre Therapeutics, Inc.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$93.81
52-Week Range
$23.01 – $110.64
Market Cap
$9.64B
P/E (TTM)
—
EPS (TTM)
-2.49
Dividend Yield
0.00%
Advanced Metrics
Price/Book
10.08
PEG Ratio
—
Return on Equity
-35.03%
Return on Assets
-24.95%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
27.39
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-95.36M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$8.71B

Market Snapshot

About

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immunological and inflammatory diseases. The company is advancing a pipeline of product candidates targeting areas of significant unmet medical need. Spyre Therapeutics aims to bring novel treatment options to patients with serious immune-mediated conditions.